Enzutix 40 mg Capsule
PDF Leaflet Revision Date: 24 January 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of metastatic castration-resistant prostate cancer in adult men.
Dosage (summary)
160 mg (4 x 40 mg capsules) once daily.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in women; potential harm to unborn child.
Key Drug Interactions
- CYP2C8 inhibitors
- CYP3A4 inhibitors
- Warfarin
Contraindications
- Hypersensitivity to enzalutamide
- Not for use in women
Common side effects
- Fatigue
- Hot flush
- Headache
- Fractures
- Hypertension
Counselling Points
- Swallow capsules whole with water
- Use condoms during treatment
- Monitor for seizures
Serious warnings
- Risk of seizure
- Posterior reversible encephalopathy syndrome
Important Disclaimer
The Enzutix 40 mg Capsule professional information leaflet below is the property of Eurolab and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
